MUC5AC and asthma: Our in vivo and in vitro experiments showed that SZYQD and its main active component luteolin play a therapeutic role in relieving asthma symptoms by reducing inflammation and mucus overproduction, which was associated with decreased IL-6 and MUC5AC expression.